Barca's Messi sees red as Bilbao claim Super Cup glory    Egypt detects 890 new coronavirus cases; 56 fatalities on Sunday    Juve's title run at risk following 2-0 loss at Inter Milan    Egypt's general intelligence chief delivers Sisi's message to Palestinian president    Egypt's new Aflemha Online Film Festival will celebrate women filmmakers    State revenues will likely fall by EGP 150 bln in FY 2020/21 on Covid-19    Orascom-Siemens-Arab Contractors consortium signs MoU to build high-speed rail system    Gut bacteria tied to Covid-19 severity    Egypt receives 19 rail carriages from Russia under mega deal    Transmar succeeded in promoting trade, doubling reefer container shipping    World Bank provides $200m loan to Egypt for air quality monitoring projects    Egypt detects 887 new coronavirus cases; 54 fatalities on Saturday    CBE offers EGP 16bn T-bills on Sunday    Tennis: Australian Open arrivals hit by 4 COVID-19 positive tests    Facebook to ban ads promoting weapon accessories, protective gear in US    US state capitals, Washington on alert for possible pro-Trump armed protests    In Photos: Egyptian archaeological mission at Saqqara Necropolis announces new major discoveries    Armin Laschet picked as new leader of Germany's CDU party    Bank ABC acquires Blom Bank Egypt for $480 million: Sources    Egypt's Sisi discusses bilateral ties, regional developments with Sudanese delegation    Egypt's Mostaqbal Watan party dominates the leading posts of parliament's 25 committees    Egypt's budget deficit to GDP ratio receded to 3.6% in first half of FY2020/21, revenues rose by 16%    Mubarak-era politician Safwat El-Sherif dies aged 88    Egypt's president, Siemens CEO discuss final deal on construction of electric train system    Hollywood actor Mena Massoud visits Giza pyramids, says is proud of Egyptian culture    Egypt reopens airspace and resumes flights with Qatar    Egypt, Tunisia to establish maritime trade route    Egypt eyes gradual return for tourism after revenues fall to $4 bln in 2020    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Nassef Sawiris plans to up his stake in owner of New York Knicks, Rangers    Cairo International Book Fair suspended for five months over coronavirus concerns    Egypt unveils largest archaeological discovery in 2020 with over 100 intact sarcophagi    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Global Finance: Egypt's Tarek Amer among the world's top 20 central bank governors    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





CEO says AstraZeneca likely to run new global trial of COVID-19 vaccine
Published in Ahram Online on 26 - 11 - 2020

AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief executive was quoted as saying on Thursday amid questions over the results from its late-stage study.
Instead of adding the trial to an ongoing U.S. process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage, Pascal Soriot was quoted as saying in a Bloomberg News report.
"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Soriot was quoted as saying.
Soriot said it would probably be another "international study, but this one could be faster because we know the efficacy is high so we need a smaller number of patients".
The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.
Several scientists have raised doubts about the robustness of results released on Monday showing the experimental vaccine was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose.
Soriot said he did not expect the additional trial to delay UK and European regulatory approvals.
AstraZeneca told Reuters earlier on Thursday that administering of the half dose had been reviewed and approved by independent data safety monitors and the UK regulator, adding that the regulator publicly confirmed there was "no concern".
Clearance from the U.S. Food and Drug Administration (FDA) may take longer though because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, especially given the questions over the results, Soriot said.
Authorisation in some countries is still expected before the end of the year, he added.
AstraZeneca research chief Mene Pangalos told Reuters on Monday that researchers had stumbled upon the half-dose regime by accident, saying a sub-group of the trial was given a smaller initial dose by mistake.
Earlier he had said that the firm would start discussions with the FDA to change the design of its experimental COVID-19 vaccine trial to add the more-effective dosage regime.
Running an additional trial might not be too much of a complication for the British drugmaker in the race to develop a successful vaccine to help tame the pandemic, which has killed more than a million people and roiled the global economy.
Helen Fletcher, Professor of Immunology at the London School of Hygiene & Tropical Medicine, said that another trial would not necessarily delay getting a green light as efficacy in the higher dose regime still met the World Health Organisation's target, and it was not unusual to run new studies on approved vaccines.
"It's entirely possible AZ and Oxford could license the high dose and then quickly seek an amendment to use the low dose when they have sufficient data," she said.
The vaccine is one of three that could get approved before the end the year. Earlier this month, Pfizer and Moderna reported that their vaccines were about 95% effective in preventing illness, setting the bar sky-high.
Even so, the AstraZeneca shot developed with Oxford University is cheaper to make, easier to distribute and faster to scale up than its rivals.
A peer-reviewed analysis of the trial data will be published in a medical journal in the coming weeks.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is continuing its rolling review of the vaccine, the regulator's chief executive June Raine said in an email on Thursday.
She said "Any vaccine must undergo robust clinical trials in line with international standards, with oversight provided by the Medicines and Healthcare products Regulatory Agency (MHRA), and no vaccine would be authorised for supply in the UK unless the expected standards of safety, quality and efficacy are met."
The European Medicines Agency (EMA) did not immediately respond to requests for comment on the potential for another study.


Clic here to read the story from its source.